Why appetite returns

Tirzepatide's effects do not become permanent after several months of use. As the drug level falls after your last dose, its effect on appetite fades. The timing and strength of this vary, and the drug does not vanish on the day you miss an injection.

Returning hunger is not addiction withdrawal. The loss of the drug's effect combines with the body's own push to regain weight after weight loss. You deserve practical support, with no blame.

What the withdrawal trial showed

In SURMOUNT-4, everyone first took tirzepatide for 36 weeks. Those switched to placebo then gained an average of 14.0% of their week-36 body weight over the next 52 weeks. Those who stayed on tirzepatide lost a further 5.5% on average.

The 14% is measured against week-36 weight, so it does not equal 14 percentage points of original starting weight. Nor did every participant regain everything. The trial included adults without diabetes who completed the first phase. Its averages will not predict every person's result or every way of stopping.

Your reason for stopping shapes the plan

Stopping for suspected pancreatitis, pregnancy, serious side effects, too little benefit, personal preference or cost each brings different priorities. If pancreatitis is suspected, stop treatment while you are assessed. If pancreatitis is confirmed, do not restart. Never let a routine talk about maintaining weight delay urgent safety action.

If you have diabetes, stopping may mean a different glucose-lowering regimen and closer monitoring. Do not stop insulin or other needed medicines because Mounjaro is stopping. The clinician responsible should coordinate the whole plan.

Tapering has no proven record against regain

The UK label sets out no tapering programme proven to keep weight off after stopping. Results from one withdrawal trial do not prove any particular gradual reduction works. Ask your prescriber whether a suggested plan is their own approach or a regimen tested in a trial.

Do not taper on your own by drawing out leftover medicine, counting clicks or stretching the gaps between doses. These methods give an unreliable dose and hide what you are taking. If your prescriber adjusts your dose, they should write the change down clearly.

Set up follow-up before your last pen

Agree realistic meal routines, activity suited to your ability and a way to track weight and health without constant anxious checking. Discuss what would trigger a reassessment and which alternatives are open to you. Support should also look at sleep, other medicines, mobility and psychological factors in eating.

If cost is the reason, tell the service early so you can plan before the medicine runs out. If you later consider restarting, give the full length of the gap and any past side effects. An old high-strength prescription is not a safe restart dose by default. Ongoing care still helps if you decide to stay off medication.

Sources

Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.

  1. Mounjaro UK Summary of Product Characteristics, updated September 2026 medicines.org.uk
  2. NICE: prescribing, reviewing and stopping tirzepatide nice.org.uk
  3. SURMOUNT-4: continued tirzepatide for maintenance of weight reduction pmc.ncbi.nlm.nih.gov
  4. MHRA: GLP-1 medicines, what you need to know gov.uk

Spotted something out of date? Report a mistake.